Mogroside V Promotes Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells from Diabetic Mice by Altering MicroRNA Profiles

Yicai Luo; Zhimao Ye; Cuiping Li; Le Hong; Hao Li

doi:10.2174/0113862073299904240416114653

Mogroside V Promotes Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells from Diabetic Mice by Altering MicroRNA Profiles

Comb Chem High Throughput Screen. 2024 Apr 25. doi: 10.2174/0113862073299904240416114653. Online ahead of print.

Authors

Yicai Luo^{1

2}, Zhimao Ye^{1

2}, Cuiping Li², Le Hong^{1

2}, Hao Li^{1

2}

Affiliations

¹ Department of Prosthodontics, College and Affiliated Hospital of Stomatology, Guangxi Medical University, Nanning, 530021, China.
² Guangxi Key Laboratory of Oral and Maxillofacial Restoration and Reconstruction, Guangxi Medical University, Nanning, 530021, China.

PMID: 38676499
DOI: 10.2174/0113862073299904240416114653

Abstract

Background: Mogroside V (MV), a triterpene glycoside, exhibits diverse biological functions. However, its ability to promote the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) under diabetic conditions is yet to be elucidated.

Objective: To study the regulation of osteogenic differentiation of BMSCs in diabetic mice by MV and determine the potential mechanism.

Methods: BMSCs were isolated from both normal (referred to as N-BMSCs) and diabetic (referred to as DM-BMSCs) C57BL/6 mice. DM-BMSCs were treated with different concentrations of MV for varying durations, and cell viability was detected using the cell counting kit-8 assay. Following 2 weeks of osteogenic induction, osteogenic differentiation capability was evaluated using alizarin red S staining, alkaline phosphatase (ALP) activity analysis, and quantitative real-time reverse transcription polymerase chain reaction. Furthermore, the microRNA (miRNA) expression profiles of N-BMSCs, DM-BMSCs, and DM-BMSCs treated with MV were tested using high-throughput sequencing.

Results: Treatment with MV enhanced the viability of DM-BMSCs and mitigated the reduction of calcium nodule deposition, ALP activity, and mRNA expression of ALP, osteocalcin, and runt-related transcription factor 2. Of the analyzed miRNAs, miR-10b-5p was the only one that exhibited differential expression in N-BMSCs, DM-BMSCs, and DM-BMSCs treated with MV. An analysis of the top four protein clusters based on KEGG suggested that the target genes of differentially expressed miRNAs were closely linked to the PI3K/AKT pathway.

Conclusion: MV significantly enhances the viability and osteogenic differentiation of BMSCs under diabetic conditions. The alteration of miRNA profiles provides a foundation for further research into the regulatory role of miRNAs and MV in this process.

Keywords: Bioinformatics.; Bone marrow mesenchymal stem cells; Diabetes; Mogroside V; Osteogenic differentiation; microRNA.